Rivastigmine 3M Health Care Ltd
rivastigmine
Table of contents
Overview
The marketing authorisation for Rivastigmine 3M Health Care Ltd has been withdrawn at the request of the marketing authorisation holder.
-
List item
Rivastigmine 3M Health Care Ltd : EPAR - Summary for the public (PDF/543.73 KB)
First published: 14/04/2014
Last updated: 18/09/2014
EMA/58565/2014 -
-
List item
Rivastigmine 3M Health Care Ltd : EPAR - Risk-management-plan summary (PDF/554.05 KB)
First published: 14/04/2014
Last updated: 18/09/2014
Authorisation details
| Product details | |
|---|---|
| Name |
Rivastigmine 3M Health Care Ltd
|
| Agency product number |
EMEA/H/C/003824
|
| Active substance |
rivastigmine
|
| International non-proprietary name (INN) or common name |
rivastigmine
|
| Therapeutic area (MeSH) |
Alzheimer Disease
|
| Anatomical therapeutic chemical (ATC) code |
N06DA03
|
Generic |
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines. |
| Publication details | |
|---|---|
| Marketing-authorisation holder |
3M Health Care Limited
|
| Revision |
1
|
| Date of issue of marketing authorisation valid throughout the European Union |
03/04/2014
|
| Contact address |
1 Morley Street
Loughborough Leicestershire LE11 1EP United Kingdom |
Product information
19/08/2014 Rivastigmine 3M Health Care Ltd - EMEA/H/C/003824 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Psychoanaleptics
-
Anticholinesterases
Therapeutic indication
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.